Please login to the form below
Dupixent
This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.
Novartis shares promising phase 3 results for BTK inhibitor in chronic hives
Sanofi and Regeneron’s Dupixent is currently on track to receive approval for uncontrolled CSU this year. ... Dupixent is a fully human monoclonal antibody that inhibits the signalling of the interleukin-4 and interleukin-13 pathways, shown in the
Latest news
-
Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial
Sanofi and Regeneron’s Dupixent (dupilumab) was approved by the FDA in September last year as the first and only treatment indicated for prurigo nodularis.
-
Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial
The positive results for amlitelimab come just a few months after Sanofi and Regeneron’s Dupixent (dupilumab) was approved by the European Commission to treat severe atopic dermatitis in children aged ... The approval made Dupixent the first targeted
-
Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease
The study also showed a 160ml improvement in lung function from baseline at 12 weeks in the Dupixent-treated cohort versus 77ml in the control group. ... Dupixent has already received regulatory approvals for use in certain patients with atopic dermatitis
-
Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine
Sanofi and Regeneron’s Dupixent (dupilumab) was associated with significant improvements in uncontrolled prurigo nodularis symptoms, according to positive phase 3 results recently published in Nature Medicine. ... Dupixent is already approved to treat
-
Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
The announcement comes just days after Regeneron and partner Sanofi’s Dupixent (dupilumab) was approved by the European Commission to treat severe atopic dermatitis in children aged six months to five ... The approval, which follows a positive opinion
More from news
Approximately 39 fully matching, plus 38 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
